Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

    NEXT STORY
    Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
    PREV STORY
    Digital Radiography Market to Reach US$ 2,978.3 Mn by 2026, FDA Clearance to Philips and Other Companies to Enable Growth, says Fortune Business Insights
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

    author_avatar
    NASDAQ Market News

    RedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium

    TEL-AVIV, Israel, Jan. 04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” ...

    author_avatar
    NASDAQ Market News

    Allena Pharmaceuticals Appoints Allene Diaz to its Board of Directors

    author_avatar
    NASDAQ Market News